Gerallt Williams, PhD, takes a look at the market forces driving DPI innovation and focuses on a novel solution that has simplicity at the heart of its design, and which hopes to address the growing pressure to reduce healthcare costs, as well as the needs of new markets, arising from emerging economies in South America, India, and China.
PACKAGING – The Impact of Packaging at the Clinical Interface of Vaccine, Healthcare Worker & Patient
Brian Lynch, MBA; and Philip Song, MSc; indicate further adoption of vaccines packaged in PFS is expected to continue, for both new and currently marketed vaccines, particularly as clinicians and vaccine enterprise stakeholders look more closely at the implication of packaging at the user interface and understand the benefits PFS offer in terms of greater efficiency and advancing best care.
Johannes BartholomÃ¤us, PhD; Judy Ashworth, MD; Hans-Jürgen Stahlberg, MD; Eric Galia, PhD; and Kai Strothmann, PhD; examine an innovative drug delivery platform that can significantly raise the hurdle for misuse or abuse of tablets by routes of administration that require the product to first be crushed.
Dinesh Haswani, PhD; John Nagel, MBA; Derek Moe, PhD; and Ehab Hamed, PhD; say formulations developed using OraGuard technology provide overlapping resistance against various tampering methods, such as crushing and ingestion, chewing, small-volume extract
DRUG DEVICES – The Rise of the Bolus Injector – A New Device Class Enabling Long-Duration Subcutaneous Administration of Large-Dose Volume Biologics
Alan Shortall reviews Unilife’s bolus injectors for large-dose volume injectable therapies, and how Unilife is already working with a number of companies to customize each device to address the specific needs of a series of pipeline and approved molecules.
DRUG DELIVERY – Hyaluronic Acid: An Ideal Ingredient for Slow-Release Formulations for Osteoarthritis Treatment
Morten J. Maltesen, PhD; and Ole M. Dall, MSc; believe that in addition to its physiological and biological effects in the joints, HA exhibits significant structural and rheological properties that make it an attractive carrier for drug delivery applications.
In this exclusive Drug Development & Delivery annual report, handheld injection experts provide their thoughts about the various factors backing the adoption of the devices including ease of use, pain-free delivery, and differentiation for product line extensions.
DRUG DESIGN – Fragment-Based Drug Design: Delivering Drugs That Hit Multiple targets, Leveraging Insights From Systems Biology
David Pompliano, PhD, believes the next generation of pharmaceuticals will have to hit more than one target simultaneously in order to fully exploit the knowledge gained from systems biology, and currently, the most effective strategy to achieve this rational design goal is computational fragment-based drug design (CFBDD).
Jean C. Sung, PhD, says that while delivery of drugs via first-generation inhaled drug systems provides great advantages over oral or intravenous delivery, these systems also have inherent limitations, creating a tremendous opportunity for next-generation inhaled delivery platforms.
EXECUTIVE INTERVIEW – Caisson Biotech: Innovatio in Drug Delivery Using a Naturally Occurring Sugar Molecule
Thomas Harlan, CEO of Caisson, discusses how his company is improving the quality and delivery of numerous medications, making life easier for patients, and offering new ways for companies to enhance their drug pipeline.
EXCLUSIVE ONLINE CONTENT
Vectura Group plc, an industry-leading inhalation CDMO, recently confirmed the announcement made by its partner Hikma Pharmaceuticals PLC, which has received a minor complete response letter (CRL) from the US FDA in….
Thomas H. Lee Partners, L.P. and Frazier Healthcare Partners recently announced they have acquired Adare Pharmaceuticals, which will be rebranded Adare Pharma Solutions, a leading specialty contract development….
Vectura Partners With Monash University to Support Development of Inhaled Oxytocin to Prevent Postpartum Haemorrhage
Vectura Group plc recently announced it has signed an agreement with Monash University’s Institute of Pharmaceutical Sciences (MIPS) to develop inhaled oxytocin delivered via a….
Evonik recently announced the qualification of an advanced aseptic filling line for complex parenteral drug products at its FDA-inspected Birmingham….
Alimera Sciences, Inc. recently announced it has enrolled the first patient in the company’s NEW DAY clinical trial, a randomized, controlled, multi-center study designed to…